Form 4: MaxCyte Director Yasir B. Al-Wakeel Reports Acquisition of Shares and Stock Options

Director Yasir B. Al-Wakeel reports acquisition of 21,367 shares of common stock and 40,701 stock options in MaxCyte, Inc.

Summary

• On June 11, 2024, Yasir B. Al-Wakeel, a director of MaxCyte, Inc. (MXCT), acquired 21,367 shares of common stock.
• These shares were received as restricted stock units (RSUs), each representing a contingent right to receive one share of MaxCyte's common stock.
• Al-Wakeel also acquired 40,701 stock options with an exercise price of $4.68.
• The stock options were granted on June 11, 2024, and are exercisable from June 10, 2034.
• The annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors.
• The shares underlying the grant vest on June 11, 2025, subject to continuous service as a director.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a director suggests confidence, but it's a routine transaction.

Positives

• The acquisition of shares and stock options by a director signals confidence in the company's future prospects.
• The vesting of the RSU grant is tied to continued service, aligning the director's interests with the long-term success of the company.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of the RSU grant on June 11, 2025, indicates an expectation of continued service by the director.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. These transactions are subject to regulatory scrutiny to prevent insider trading and ensure transparency.

Key Dates